BLISSGVS (BLISSGVS): Promoter Buying
Bliss GVS Pharma has filed an addendum to the public announcement and detailed public statement for the open offer made by Anupam Rasayan Limited, according to an NSE filing dated 19 July. The addendum relates to the addition of a Persons Acting in Concert (PAC) to the open offer structure. This type of promoter-related buying activity, where acquirers strengthen their position through open offers, is classified as a bullish catalyst in event-driven analysis.
Events like this have historically shown a 65.2% win rate across 23 comparable instances in Strota's database, with a net edge of 1.222%. These base rates reflect how similar promoter-buying events have performed on average across past stocks, not a forecast for Bliss GVS Pharma specifically.
The stock currently trades at a price-to-earnings ratio of 40.33 and price-to-book of 4.29, with a market capitalisation of ₹5,137 crore. Return on equity stands at 11.6%, while the dividend yield is 0.41%. On 29 June, an institutional block deal saw MATEUS LTD buy shares worth ₹56.35 crore from ARIAN INVESTMENT LTD at the same value.
The filing confirms the open offer addendum but does not establish whether the transaction will proceed at a premium to current prices, the final acceptance ratio, or how the resignation of CEO Narsimha Shibroor Kamath effective 14 July 2026 may affect the company's operations. The data records what has been disclosed and what similar events have historically shown, not the probability of success for this specific transaction.
The catalyst
Bliss GVS Pharma Limited has informed the Exchange about Addendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC. (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Promoter Buying tends to continue — the move went bullish in about 65.2% of next sessions (net 1.222% after drift and cost, n=23). A base rate, not a forecast for this stock.
BLISSGVS right now
P/E 40.33. Full BLISSGVS analysis →
Sources
- Bliss GVS Pharma Limited has informed the Exchange about Addendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC. — NSE
- Is It Smart To Buy Bliss GVS Pharma Limited (NSE:BLISSGVS) Before It Goes Ex-Dividend? — simplywall.st
- Should You Be Adding Bliss GVS Pharma (NSE:BLISSGVS) To Your Watchlist Today? — simplywall.st
- Bliss GVS Pharma Board Meeting Scheduled on May 12, 2026 to Approve Q4 FY26 Results and Final Dividend — scanx.trade
- Bliss GVS Pharma's (NSE:BLISSGVS) 37% CAGR outpaced the company's earnings growth over the same three-year period — webull.com.my
Keep digging
- BLISSGVS — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.